Sandoz Group Ltd (SDZNY) on Wednesday announced that the U.S. Food and Drug Administration has approved an expanded label for Enzeevu, broadening its use to treat multiple retinal diseases.
The updated approval expands Enzeevu's indications to include macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR), and diabetic macular edema (DME), in addition to its previously approved use for neovascular (wet) age-related macular degeneration (nAMD).
Sandoz said it plans to launch Enzeevu in the U.S. in the fourth quarter of 2026, or earlier.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.